KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Restructuring Costs (2016 - 2018)

Vertex Pharmaceuticals has reported Restructuring Costs over the past 10 years, most recently at -$4000.0 for Q4 2018.

  • Quarterly results put Restructuring Costs at -$4000.0 for Q4 2018, down 101.03% from a year ago — trailing twelve months through Sep 2019 was -$4000.0 (down 100.7% YoY), and the annual figure for FY2018 was -$184000.0, down 101.29%.
  • Restructuring Costs for Q4 2018 was -$4000.0 at Vertex Pharmaceuticals, down from $174000.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for VRTX hit a ceiling of $40.8 million in Q3 2014 and a floor of -$3.3 million in Q1 2015.
  • Median Restructuring Costs over the past 5 years was $365000.0 (2016), compared with a mean of $3.4 million.
  • Biggest five-year swings in Restructuring Costs: soared 15766.67% in 2014 and later tumbled 152.88% in 2015.
  • Vertex Pharmaceuticals' Restructuring Costs stood at $4.2 million in 2014, then crashed by 63.4% to $1.5 million in 2015, then crashed by 85.3% to $224000.0 in 2016, then surged by 72.77% to $387000.0 in 2017, then tumbled by 101.03% to -$4000.0 in 2018.
  • The last three reported values for Restructuring Costs were -$4000.0 (Q4 2018), $174000.0 (Q3 2018), and -$62000.0 (Q2 2018) per Business Quant data.